SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hui S, Slemenda CW, Johnston CC 1988 Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81: 18041809.
  • 2
    Schaffler MB, Choi K, Milgrom C 1995 Aging and matrix microdamage accumulation in human compact bone. Bone 17: 521525.
  • 3
    Mori S, Harruff R, Ambrosius W, Burr DB 1997 Trabecular bone volume and microdamage accumulation in femoral heads of women with and without femoral neck fracture. Bone 21: 521526.
  • 4
    Fazzalari NL, Forwood MR, Smith K, Manthey BA, Herreen P 1998 Assessment of cancellous bone quality in severe osteoarthrosis: bone mineral density, mechanics, and microdamage. Bone 22: 3818.
  • 5
    Frost HM 1991 Some ABC's of skeletal pathophysiology. 5. Microdamage physiology. Calcif Tissue Int 49: 22931.
  • 6
    Frost HM 1998 A brief review for orthopedic surgeons: fatigue damage (microdamage) in bone (its determinants and clinical implications). J Orthop Sci 3: 27281.
  • 7
    Fleisch HA 1997 Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29: 5562.
  • 8
    Fleisch H 1997 Bisphosphonates in bone disease—from the laboratory to the patient, 3rd Ed. The Parthenon Publishing Group, New York, NY, U.S.A.
  • 9
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 15351541.
  • 10
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB 1997 Treatment with alendronate prevents fractures in women at higher risk: Results from the fracture intervention trial. Arch Intern Med 157: 26172624.
  • 11
    Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Jr., Adami S, Harris ST, Santora ACn, Hirsch LJ, Oppenheimer L, Thompson D 1997 Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277: 11591164.
  • 12
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 207782.
  • 13
    Eastell R, Minne H, Sorensen O, Hooper M, Ritter-Hrncrick C, Pack S, Roumagnac I, Ethgen D, Reginster JY 1999 Risedronate reduces fracture risk in women with established postmenopausal osteoporosis. Calcif Tissue Int 64(1 Suppl): 43 S.
  • 14
    Watts N, Hangartner T, Chesnut C, Genant H, Miller P, Eriksen E, Chines A, Axelrod D, McKeever C 1999 Risedronate treatment prevents vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 64(1 Suppl): 43S.
  • 15
    Flora L, Hassing GS, Cloyd GG, Bevan JA, Parfitt AM, Villanueva AR 1981 The long term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 3: 289300.
  • 16
    Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14(4): 595608.
  • 17
    Steiniche T, Hasling C, Charles P, Eriksen EF, Melsen F, Mosekilde L 1991 The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime. Bone 12: 15563.
  • 18
    Storm T, Steiniche T, Thamsborg G, Melsen F 1993 Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8: 199208.
  • 19
    Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 257786.
  • 20
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 14751480.
  • 21
    Forwood MR, Burr DB, Takano Y, Eastman DF, Smith PN, Schwardt JD 1995 Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 16: 643650.
  • 22
    Balena R, Markatos A, Seedor JG, Gentile M, Stark C, Peter CP, Rodan GA 1996 Long-term safety of the aminobisphosphonate alendronate in adult dogs. 2. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther 276: 277283.
  • 23
    Motoie H, Nakamura T, O'uchi N, Nishikawa H, Kanoh H, Abe T, Kawashima H 1995 Effects of bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 10: 910920.
  • 24
    Flora L, Hassing GS, Parfitt AM, Villanueva AR 1980 Comparative skeletal effects of two diphosphonates in dogs. Metab Bone Dis Relat Res 2(Suppl): 389407.
  • 25
    Gibbs CJ, Aaron JE, Peacock M 1986 Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. BMJ 292: 12271229.
  • 26
    Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ 1994 Bisphosphonates: Sturucture-activity relationshipstherapeutic implication. In: HeerscheJHM, KanisJA (eds.) BoneMineral Research, 8th Ed. Elsevier Science, Amsterdam, The Netherls, pp. 265306.
  • 27
    Norman TL, Yeni YN, Brown CU, Wang Z 1998 Influence of microdamage on fracture toughness of the human femur and tibia. Bone 23: 303306.